Mitochondria Profoundly Influence Apolipoprotein E Biology.
暂无分享,去创建一个
K. Peterson | H. Wilkins | L. Novikova | Xiaowan Wang | I. Weidling | A. Berkowicz | S. R. Chowdhury | Alexander P. Gabrielli | B. Menta | Amol Ranjan | R. Swerdlow | Amol Ranjan | Heather M. Wilkins | Ian W. Weidling
[1] Joshua T. Burdick,et al. A common transcriptional mechanism involving R-loop and RNA abasic site regulates an enhancer RNA of APOE. , 2022, Nucleic acids research.
[2] G. Rimbach,et al. Functional diversity of apolipoprotein E: from subcellular localization to mitochondrial function , 2022, Cellular and Molecular Life Sciences.
[3] A. Goate,et al. The role of mitochondrial genome abundance in Alzheimer's disease , 2022, medRxiv.
[4] Christopher D. Brown,et al. Identifying differential regulatory control of APOE ɛ4 on African versus European haplotypes as potential therapeutic targets , 2022, Alzheimer's & dementia : the journal of the Alzheimer's Association.
[5] P. D. De Jager,et al. Characterization of mitochondrial DNA quantity and quality in the human aged and Alzheimer’s disease brain , 2021, Molecular Neurodegeneration.
[6] D. Bennett,et al. Neuronal ApoE upregulates MHC-I expression to drive selective neurodegeneration in Alzheimer’s disease , 2021, Nature Neuroscience.
[7] H. Anderson,et al. Bioenergetic and inflammatory systemic phenotypes in Alzheimer’s disease APOE ε4‐carriers , 2021, Aging cell.
[8] A. Picca,et al. Cell Death and Inflammation: The Role of Mitochondria in Health and Disease , 2021, Cells.
[9] S. Yu,et al. C/EBPβ is a key transcription factor for APOE and preferentially mediates ApoE4 expression in Alzheimer’s disease , 2020, Molecular Psychiatry.
[10] S. Laufer,et al. c-Jun N-Terminal Kinase Inhibitors as Potential Leads for New Therapeutics for Alzheimer’s Diseases , 2020, International journal of molecular sciences.
[11] R. Swerdlow,et al. Mitochondrial DNA Manipulations Affect Tau Oligomerization. , 2020, Journal of Alzheimer's disease : JAD.
[12] D. Michaelson,et al. Altered mitochondrial dynamics and function in APOE4-expressing astrocytes , 2020, Cell Death & Disease.
[13] M. Sabbagh,et al. Effect of ApoE isoforms on mitochondria in Alzheimer disease , 2020, Neurology.
[14] C. Giorgi,et al. The Role of Mitochondria in Inflammation: From Cancer to Neurodegenerative Disorders , 2020, Journal of clinical medicine.
[15] G. Bu,et al. Apolipoprotein E and Alzheimer disease: pathobiology and targeting strategies , 2019, Nature Reviews Neurology.
[16] D. Blackburn,et al. Ursodeoxycholic Acid Improves Mitochondrial Function and Redistributes Drp1 in Fibroblasts from Patients with Either Sporadic or Familial Alzheimer's Disease , 2018, Journal of molecular biology.
[17] Liqin Zhao,et al. Human ApoE Isoforms Differentially Modulate Brain Glucose and Ketone Body Metabolism: Implications for Alzheimer's Disease Risk Reduction and Early Intervention , 2018, The Journal of Neuroscience.
[18] L. Kritharides,et al. Cell-specific production, secretion, and function of apolipoprotein E , 2018, Journal of Molecular Medicine.
[19] R. Swerdlow. Mitochondria and Mitochondrial Cascades in Alzheimer’s Disease , 2017, Journal of Alzheimer's disease : JAD.
[20] A. Fagan,et al. ApoE4 markedly exacerbates tau-mediated neurodegeneration in a mouse model of tauopathy , 2017, Nature.
[21] R. Swerdlow,et al. Platelet cytochrome oxidase and citrate synthase activities in APOE ε4 carrier and non-carrier Alzheimer's disease patients , 2017, Redox biology.
[22] B. Wieringa,et al. The SH-SY5Y cell line in Parkinson’s disease research: a systematic review , 2017, Molecular Neurodegeneration.
[23] G. Landreth,et al. LXR Regulation of Brain Cholesterol: From Development to Disease , 2016, Trends in Endocrinology & Metabolism.
[24] A. Friedman. C/EBPα in normal and malignant myelopoiesis , 2015, International Journal of Hematology.
[25] R. Mahley,et al. Apolipoprotein E Sets the Stage: Response to Injury Triggers Neuropathology , 2012, Neuron.
[26] R. Swerdlow. Mitochondria and cell bioenergetics: increasingly recognized components and a possible etiologic cause of Alzheimer's disease. , 2012, Antioxidants & redox signaling.
[27] L. Bekris,et al. Functional Analysis of APOE Locus Genetic Variation Implicates Regional Enhancers in the Regulation of Both TOMM40 and APOE , 2011, Journal of Human Genetics.
[28] Ying Xia,et al. c-Jun, at the crossroad of the signaling network , 2011, Protein & Cell.
[29] David M Holtzman,et al. Human Apoe Isoforms Differentially Regulate Brain Amyloid-β Peptide Clearance Nih Public Access , 2022 .
[30] R. Mahley,et al. Apolipoprotein E4 Domain Interaction Mediates Detrimental Effects on Mitochondria and Is a Potential Therapeutic Target for Alzheimer Disease* , 2010, The Journal of Biological Chemistry.
[31] G. Fiskum,et al. Neuroprotection through stimulation of mitochondrial antioxidant protein expression. , 2010, Journal of Alzheimer's disease : JAD.
[32] E. Choi,et al. Pathological roles of MAPK signaling pathways in human diseases. , 2010, Biochimica et biophysica acta.
[33] E. Reiman,et al. Reduced posterior cingulate mitochondrial activity in expired young adult carriers of the APOE ε4 allele, the major late-onset Alzheimer's susceptibility gene. , 2010, Journal of Alzheimer's disease : JAD.
[34] L. Opitz,et al. A New Paradigm for MAPK: Structural Interactions of hERK1 with Mitochondria in HeLa Cells , 2009, PloS one.
[35] C. Chu,et al. Mitochondrial kinases in Parkinson's disease: converging insights from neurotoxin and genetic models. , 2009, Mitochondrion.
[36] T. Mazzone,et al. Peroxisome Proliferator-activated Receptor γ Stimulation of Adipocyte ApoE Gene Transcription Mediated by the Liver Receptor X Pathway* , 2009, Journal of Biological Chemistry.
[37] T. Mazzone,et al. Oxidative Stress Regulates Adipocyte Apolipoprotein E and Suppresses Its Expression in Obesity , 2008, Diabetes.
[38] G. Schellenberg,et al. Multiple SNPs within and surrounding the apolipoprotein E gene influence cerebrospinal fluid apolipoprotein E protein levels. , 2008, Journal of Alzheimer's disease : JAD.
[39] M. Simionescu,et al. Inflammatory Signaling Pathways Regulating ApoE Gene Expression in Macrophages* , 2007, Journal of Biological Chemistry.
[40] George Perry,et al. Alzheimer disease, the two-hit hypothesis: an update. , 2007, Biochimica et biophysica acta.
[41] V. Haroutunian,et al. Correlation of the clinical severity of alzheimer’s disease with an aberration in mitochondrial DNA (mtDNA) , 2001, Journal of Molecular Neuroscience.
[42] D. Lahiri. Apolipoprotein E as a target for developing new therapeutics for Alzheimer’s disease based on studies from protein, RNA, and regulatory region of the gene , 2007, Journal of Molecular Neuroscience.
[43] R. Mahley,et al. Apolipoprotein E4: a causative factor and therapeutic target in neuropathology, including Alzheimer's disease. , 2006, Proceedings of the National Academy of Sciences of the United States of America.
[44] R. Mahley,et al. Lipid- and receptor-binding regions of apolipoprotein E4 fragments act in concert to cause mitochondrial dysfunction and neurotoxicity. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[45] M. Beal,et al. Alzheimer's brains harbor somatic mtDNA control-region mutations that suppress mitochondrial transcription and replication. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[46] Xiongwei Zhu,et al. Alzheimer's disease: the two-hit hypothesis , 2004, The Lancet Neurology.
[47] R. Mahley,et al. Astroglial Regulation of Apolipoprotein E Expression in Neuronal Cells , 2004, Journal of Biological Chemistry.
[48] T. Lanz,et al. Dendritic spine loss in the hippocampus of young PDAPP and Tg2576 mice and its prevention by the ApoE2 genotype , 2003, Neurobiology of Disease.
[49] D. Ramji,et al. CCAAT/enhancer-binding proteins: structure, function and regulation. , 2002, The Biochemical journal.
[50] J. Hardy,et al. The Amyloid Hypothesis of Alzheimer ’ s Disease : Progress and Problems on the Road to Therapeutics , 2009 .
[51] Xiongwei Zhu,et al. Differential activation of neuronal ERK, JNK/SAPK and p38 in Alzheimer disease: the ‘two hit’ hypothesis , 2001, Mechanisms of Ageing and Development.
[52] D. Talmage,et al. Apolipoprotein E Inhibits Serum-stimulated Cell Proliferation and Enhances Serum-independent Cell Proliferation* , 2001, The Journal of Biological Chemistry.
[53] R. Swerdlow,et al. Alzheimer's disease cybrids replicate β‐amyloid abnormalities through cell death pathways , 2000 .
[54] J. Wands,et al. Mitochondrial DNA Damage as a Mechanism of Cell Loss in Alzheimer's Disease , 2000, Laboratory Investigation.
[55] R. Mahley,et al. Apolipoprotein E: far more than a lipid transport protein. , 2000, Annual review of genomics and human genetics.
[56] Jiahuai Han,et al. The p38 signal transduction pathway: activation and function. , 2000, Cellular signalling.
[57] R. Swerdlow,et al. Cyclosporin A increases resting mitochondrial membrane potential in SY5Y cells and reverses the depressed mitochondrial membrane potential of Alzheimer's disease cybrids. , 1998, Biochemical and biophysical research communications.
[58] R. Davis,et al. Cybrids in Alzheimer's disease: A cellular model of the disease? , 1997, Neurology.
[59] E. Zandi,et al. AP-1 function and regulation. , 1997, Current opinion in cell biology.
[60] W. Parker,et al. Creation and Characterization of Mitochondrial DNA‐Depleted Cell Lines with “Neuronal‐Like” Properties , 1996, Journal of neurochemistry.
[61] R. Swerdlow,et al. Origin and functional consequences of the complex I defect in Parkinson's disease , 1996, Annals of neurology.
[62] L. Mahadevan,et al. Anisomycin-activated protein kinases p45 and p55 but not mitogen-activated protein kinases ERK-1 and -2 are implicated in the induction of c-fos and c-jun , 1994, Molecular and cellular biology.